Why ImmunityBio (IBRX) Is Up 18.5% After Early VA Uptake of ANKTIVA and Improving Financials

• ImmunityBio, Inc. announced that the Michael E. DeBakey VA Medical Center in Houston recently became one of the first VA hospitals in the U.S. to treat a veteran with ANKTIVA®, its FDA-approved immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
• This milestone highlights the real-world adoption of ANKTIVA® within a key patient group at increased risk, while ImmunityBio also reported sharply increased revenues and reduced net losses for the latest quarter.
• Next, we’ll explore how early ANKTIVA® uptake among veterans could shape ImmunityBio’s overall investment narrative.

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is ImmunityBio's Investment Narrative?

To be a shareholder in ImmunityBio today, you really have to believe in ANKTIVA’s ability to transform the treatment outlook for patients and generate meaningful market adoption. The recent news that the Michael E. DeBakey VA Medical Center is among the first VA hospitals in the U.S. using ANKTIVA in the veteran population is a visible step toward wider real-world uptake, especially given the higher incidence of bladder cancer in this group. With ImmunityBio’s revenue rising and net losses narrowing last quarter, these early signs of adoption could signal progress for one of the company’s most important short-term catalysts: accelerating sales growth for ANKTIVA following its FDA approval. At the same time, the main risks haven’t disappeared, lingering legal challenges, heavy ongoing losses, follow-on equity offerings, and a high price-to-sales ratio compared to peers still weigh on the investment case. This latest adoption event at the VA could help validate the commercial thesis, but the bottom line remains that commercial traction, not regulatory progress alone, will be key from here.

But investors should also keep in mind ongoing dilution from recent equity offerings. ImmunityBio's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Simply Wall St Community members have published eight fair value estimates for ImmunityBio, spanning from as low as US$0.33 to a very high US$30 per share. While you’ll see valuations that differ widely, the recent early adoption news at VA centers may influence future opinions about both upside and risk. Look across these diverse perspectives to get a broader sense of how market participants are weighing the company’s outlook.

Explore 8 other fair value estimates on ImmunityBio - why the stock might be worth over 10x more than the current price!

Build Your Own ImmunityBio Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• These 15 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com